灯盏生脉胶囊联合洛伐他汀对老年冠心病患者的疗效及机制分析

摘要/Abstract

摘要： 目的研究灯盏生脉胶囊联合洛伐他汀对老年冠心病的疗效及机制。方法选择2020年3月~2021年12月天水市第一人民医院收治的80例老年冠心病患者,根据随机数表法分为对照组和观察组。对照组服用洛伐他汀治疗,观察组服用灯盏生脉胶囊和洛伐他汀治疗。观察两组治疗有效率,检测两组的心功能指标、同型半胱氨酸（Hcy）、超敏C反应蛋白（hs-CRP）和尿酸（UA）水平,且检测两组血液流变学指标。结果观察组患者有效率明显高于对照组（P<0.05）;治疗前,两组左心室收缩末期容积（LVESV）、左心室舒张末期内径（LVEDD）、左心室射血分数（LVEF）及左心室收缩末期内径（LVESD）比较,差异无统计学意义（P>0.05）,治疗后,两组LVESV、LVEDD、LVEF和LVESD均明显改善（P<0.05）,且观察组心功能指标明显优于对照组（P<0.05）;治疗前,两组UA、hs-CRP和Hcy水平比较,差异无统计学意义（P>0.05）,治疗后,两组UA、hs-CRP和Hcy水平均明显降低（P<0.05）,且观察组UA、hs-CRP和Hcy水平明显低于对照组（P<0.05）;治疗前,两组红细胞聚集指数、血浆黏度、最大血小板聚集率和纤维蛋白原比较,差异无统计学意义（P>0.05）,治疗后,两组红细胞聚集指数、血浆黏度、最大血小板聚集率和纤维蛋白原均明显降低（P<0.05）,且观察组红细胞聚集指数、血浆黏度、最大血小板聚集率和纤维蛋白原明显低于对照组（P<0.05）。结论灯盏生脉胶囊联合洛伐他汀对老年冠心病的疗效较佳,且机制可能与降低UA、hs-CRP和Hcy水平,调节炎症因子水平有关。

关键词: 灯盏生脉胶囊, 洛伐他汀, 老年冠心病, 疗效, 作用机制

Abstract: Objective To investigate the efficacy and mechanism of Dengzhan Shengmai capsule combined with lovastatin in elderly patients with coronary heart disease. Methods 80 elderly patients with coronary heart disease admitted to Tianshui First People's Hospital from March 2020 to December 2021 were selected and divided into two groups according to the random number table method. The control group was treated with lovastatin, and the observation group was treated with Dengzhan Shengmai Capsules and lovastatin. The effective rate of treatment in the two groups was observed, the cardiac function indexes, homocysteine (Hcy), high-sensitivity C-reactive protein (hs-CRP) and uric acid (UA) levels in the two groups were detected, and the hemorheological indexes of the two groups were detected. Results The effective rate of the observation group was significantly higher than control group (P<0.05). Before treatment, there was no statistical significant difference in LVESV, LVEDD, LVEF and LVESD between the two groups (P>0.05). After treatment, LVESV, LVEDD, LVEF and LVESD in the two groups were significantly improved (P<0.05). The index was significantly better than the control group (P<0.05). Before treatment, there was no statistical significant difference in the levels of UA, hs-CRP and Hcy between the two groups (P>0.05). After treatment, the levels of UA, hs-CRP and Hcy in the two groups were significantly decreased (P<0.05). The levels of UA, hs-CRP and Hcy were significantly lower than those in the control group (P<0.05). Before treatment, there was no statistical significant difference in the erythrocyte aggregation index, plasma viscosity, maximum platelet aggregation rate and fibrinogen between the two groups (P>0.05). After treatment, the erythrocyte aggregation index, plasma viscosity, maximum platelet aggregation rate and fibrinogen between the two groups The erythrocyte aggregation index, plasma viscosity, maximum platelet aggregation rate and fibrinogen in the observation group were significantly lower than those in the control group (P<0.05). Conclusion Dengzhan Shengmai capsule combined with lovastatin has better curative effect on elderly patients with coronary heart disease, and the mechanism may be related to reducing the levels of UA, hs-CRP and Hcy, and regulating the levels of inflammatory factors.

Key words: Dengzhan Shengmai Capsule, lovastatin, coronary heart disease in the elderly, efficacy, mechanism of action

中图分类号:

R541.4

王广东. 灯盏生脉胶囊联合洛伐他汀对老年冠心病患者的疗效及机制分析[J]. 中华养生保健, 2022, 40(21): 47-50.

WANG Guang-dong. Efficacy and Mechanism of Dengzhan Shengmai Capsule combined with Lovastatin in Elderly Patients with Coronary Heart Disease[J]. ZHONGHUA YANGSHENG BAOJIAN, 2022, 40(21): 47-50.

参考文献

[1] 李文英,吕培.延丹胶囊联合阿司匹林对冠心病病人氧化应激反应指标及血清CysC、PAI-1水平的影响[J].中西医结合心脑血管病杂志,2021,19(9):1535-1539.
[2] 贺正波,束晨,张明玺.氨氯地平联合阿托伐他汀钙片对高血压合并冠心病病人免疫功能、血管内皮功能与炎症因子水平的影响[J].中西医结合心脑血管病杂志,2020,18(8):1276-1279.
[3] 李玉梅,李俊毅.养心氏片对气虚血瘀型冠心病病人NT-proBNP、心功能及中医证候评分的影响[J].中西医结合心脑血管病杂志,2021,19(11):1820-1823.
[4] 朱琪,贾海波.灯盏生脉胶囊对冠心病患者冠脉血流储备分数的影响及心肌保护作用研究[J].中药材,2020,43(5):1236-1239.
[5] 中华医学会老年医学分会高龄老年冠心病诊治中国专家.高龄老年冠心病诊治中国专家共识[J].中华老年医学杂志,2016,35(7):683-691.
[6] 许鹏,王俊杰,邹瑞.冠心病患者血清脂蛋白a、同型半胱氨酸及低密度脂蛋白水平与不良心脑血管事件的相关性分析[J].标记免疫分析与临床,2020,27(2):284-287.
[7] 王杰,单裕清,胡伟,等.冠状动脉CT血管成像定量参数与老年冠心病患者病情严重程度的相关性[J].中华老年心脑血管病杂志,2020,22(2):115-118.
[8] 贾国伟,赵明,郭志浩,等.冠心病病人LDL颗粒大小及ox-LDL水平与冠状动脉狭窄程度的相关性[J].中西医结合心脑血管病杂志, 2021,19(10):1685-1687.
[9] 常培学,李海波,许振培.银杏叶联合尼可地尔对药物洗脱支架治疗后老年冠心病患者多支病变的疗效分析[J].中华老年心脑血管病杂志,2020,22((3):265-268.
[10] 李卓伦,杨彦涛,孙志,等.基于UHPLC-Q-Orbitrap和网络药理学的灯盏生脉胶囊治疗心绞痛的机制研究[J].中草药,2021,52(12):3501-3513.
[11] 徐军伟,卢芳,钱跃磊,等.灯盏生脉胶囊联合替格瑞洛用于急性心肌梗死经皮冠状动脉介入术后的疗效及对患者凝血功能的影响[J].新乡医学院学报,2020,37(7):622-625.
[12] 娄序笙,李平.灯盏生脉胶囊联合常规疗法治疗气虚血瘀型冠状动脉粥样硬化性心脏病伴高脂血症的临床观察[J].上海中医药杂志,2020,54(12):45-49.
[13] 任良强,侯晓晓,乔平,等.灯盏生脉胶囊结合沙库巴曲缬沙坦钠片对冠心病合并慢性心衰患者血清APN、MMP-9和BNP水平的影响[J].中华中医药学刊,2022,40(1):180-183.
[14] 郭红玲,欧阳艳红,王圣,等.灯盏生脉胶囊联合单硝酸异山梨酯缓释片对老年冠心病心绞痛患者心功能、血脂及血清IL-6、CRP水平的影响[J].现代生物医学进展,2021,21(12):2373-2376,2339.
[15] Rallidis L S, Katsimardos A, Kosmas N, et al.Differential prognostic value of resistin for cardiac death in patients with coronary artery disease according to the presence of metabolic syndrome[J]. Heart and Vessels,2022,37(5):713-719.
[16] 李星,曹国军.益气温阳活血汤联合曲美他嗪对心肺气虚兼血瘀型冠心病心力衰竭患者心功能及血清BNP、hs-CRP的影响[J].现代中西医结合杂志,2020,29(14):1561-1564.
[17] Malthesh M K, Gosavi S, S S hastry, et al. Relationship of Acute ST-Elevation Myocardial Infarction with hs-CRP and Serum Iron Profile in Southern India: A Cross-sectional Study[J]. Journal of Clinical and Diagnostic Research,2020,14(11):OC5-OC8.
[18] 关泽勇,王立立.冠心病病人血清尿酸水平与冠状动脉病变稳定性,内皮功能及侧支循环形成的关系探讨[J].中西医结合心脑血管病杂志,2020,18(8):1259-1262.
[19] 申跃云,朱苏文.血浆同型半胱氨酸与慢性稳定性冠心病病人PCI术后再狭窄及预后的关系[J].中西医结合心脑血管病杂志,2021,19(5):800-803.
[20] 杨旭光,徐炳欣,赵艳,等.MTHFR C677T基因多态性对稳定性冠心病患者叶酸降低同型半胱氨酸治疗的影响[J].中国循证心血管医学杂志,2020,12(2):179-181,187.